Table 1.
Clinicopathological characteristics of ABC patients according to molecular subtypes.
| Total | Luminal A | Luminal B | HER2-enriched | Triple Negative | P value | |
|---|---|---|---|---|---|---|
| Age at diagnosis (years) | ||||||
| Mean ± SD | 46.51 ± 10.40 | 45.70 ± 10.53 | 45.86 ± 10.47 | 47.19 ± 10.71 | 47.65 ± 9.69 | 0.002 |
| ≤45 | 1125 (47.0%) | 182 (52.3%) | 504 (49.8%) | 240 (45.9%) | 199 (39.1%) | <0.001 |
| >45 | 1268 (53.0%) | 166 (47.7%) | 509 (50.2%) | 283 (54.1%) | 310 (60.9%) | |
| BMI (Kg/m2) | ||||||
| Mean ± SD | 23.89 ± 3.37 | 23.96 ± 3.42 | 23.68 ± 3.33 | 24.09 ± 3.19 | 24.07 ± 3.58 | 0.083 |
| Underweight (≤18.49) | 87 (4.1%) | 9 (2.9%) | 42 (4.6%) | 15 (3.2%) | 21 (4.6%) | 0.479 |
| Normal Weight (18.50~24.99) | 1313 (61.5%) | 194 (62.2%) | 573 (63.4%) | 276 (59.7%) | 270 (59.2%) | |
| Overweight (25.00~29.99) | 626 (29.3%) | 93 (29.8%) | 246 (27.2%) | 150 (32.5%) | 137 (30.0%) | |
| Obesity (>29.99) | 108 (5.1%) | 16 (5.1%) | 43 (4.8%) | 21(4.5%) | 28 (6.1%) | |
| Household register | ||||||
| Urban | 1146 (48.1%) | 152 (44.1%) | 490 (48.4%) | 269 (51.6%) | 235 (46.4%) | 0.010 |
| Rural | 872 (36.6%) | 123 (35.7%) | 375 (37.1%) | 167 (32.1%) | 207 (40.8%) | |
| Unknown | 367 (15.4%) | 70(20.3%) | 147(14.5%) | 85 (16.3%) | 65 (12.8%) | |
| Education | ||||||
| ≤Primary school education | 244 (10.2%) | 33 (9.6%) | 110 (10.9%) | 42 (8.0%) | 59 (11.7%) | 0.005 |
| Middle school education | 191 (8.0%) | 17 (5.0%) | 88 (8.7%) | 37 (7.1%) | 49 (9.7%) | |
| ≥ High school education | 276 (11.6%) | 33 (9.6%) | 135 (13.4%) | 48 (9.2%) | 60 (11.9%) | |
| Unknown | 1670 (70.1%) | 260(75.8%) | 677 (67.0%) | 395 (75.7%) | 338 (66.8%) | |
| Marital status (%) | ||||||
| Unmarried | 73 (3.1%) | 9 (2.6%) | 32 (3.2%) | 18 (3.5%) | 14 (2.8%) | 0.983 |
| Married | 2269 (95.7%) | 328 (96.2%) | 959 (95.6%) | 496 (95.6%) | 486 (95.9%) | |
| Widowed/divorced | 28 (1.2%) | 4 (1.2%) | 12 (1.2%) | 5 (1.0%) | 7 (1.4%) | |
| Menstrual status (%) | ||||||
| Premenopausal | 1097 (49.1%) | 163 (50.3%) | 477 (50.3%) | 246 (50.4%) | 211 (44.5%) | 0.170 |
| Postmenopausal | 1138 (50.9%) | 161 (49.7%) | 47 2(49.7%) | 242 (49.6%) | 263(55.5%) | |
| Family history | ||||||
| Yes | 111 (4.9%) | 14 (4.2%) | 48 (5.0%) | 30 (6.0%) | 19 (3.9%) | 0.442 |
| No | 2162 (95.1%) | 317 (95.8%) | 914 (95.0%) | 467 (94.0%) | 464 (96.1%) | |
| Smoking status | ||||||
| Yes | 26 (1.2%) | 4 (1.3%) | 7 (0.8%) | 7 (1.5%) | 8 (1.7%) | 0.415 |
| No | 2143 (98.8%) | 308 (98.7%) | 908 (99.2%) | 473 (98.5%) | 454 (98.3%) | |
| Drinking status | ||||||
| Yes | 36 (1.7%) | 5 (1.6%) | 15 (1.6%) | 9 (1.9%) | 7 (1.5%) | 0.976 |
| No | 2133 (98.3%) | 307 (98.4%) | 900 (98.4%) | 470 (98.1%) | 456 (98.5%) | |
| Tumor size (cm) | ||||||
| ≤ 2 | 440 (26.0%) | 80 (31.7%) | 179 (25.4%) | 95 (25.9%%) | 86 (23.1%) | 0.220 |
| 2-5 | 986 (58.2%) | 138 (54.8%) | 415 (58.9%) | 217 (59.1%) | 216 (58.1%) | |
| >5 | 269 (15.9%) | 34 (13.5%) | 110 (15.6%) | 55 (15.0%) | 70 (18.8%) | |
| Number of lymph node metastasis | ||||||
| 0 | 849 (35.5%) | 120 (34.5%) | 345 (34.1%) | 202 (38.6%) | 182 (35.8%) | 0.188 |
| 1-3 | 611 (25.5%) | 103 (29.6%) | 255 (25.2%) | 138 (26.4%) | 115 (22.6%) | |
| 3-9 | 485 (20.3%) | 70 (20.1%) | 207 (20.4%) | 97 (18.5%) | 111 (21.8%) | |
| >9 | 448 (18.7%) | 55 (15.8%) | 206 (20.3%) | 86 (16.4%) | 101 (19.8%) | |
| Pathological type (%) | ||||||
| Carcinoma in situ | 57 (2.4%) | 6 (1.8%) | 18 (1.8%) | 16 (3.1%) | 17 (3.4%) | 0.102 |
| Invasive ductal carcinoma | 1877 (80.4%) | 265 (79.3%) | 795 (80.3%) | 415 (81.2%) | 402 (80.2%) | |
| Other invasive carcinoma | 254 (10.9%) | 47 (14.1%) | 116 (11.7%) | 43 (8.4%) | 48 (9.6%) | |
| Others | 148 (6.3%) | 16 (4.8%) | 61 (6.2%) | 37 (7.2%) | 34 (6.8%) | |
| Surgery | ||||||
| Yes | 2155 (90.5%) | 316 (92.1%) | 890 (88.1%) | 495 (94.8%) | 454 (89.7%) | <0.001 |
| No | 223 (9.4%) | 27 (7.9%) | 119 (11.8%) | 25 (4.8%) | 52 (10.3%) | |
| Surgical method | ||||||
| Mastectomy | 1902 (90.6%) | 278 (92.4%) | 774 (88.9%) | 440 (90.3%) | 410 (93.2%) | 0.053 |
| Conservative surgery | 197 (9.4%) | 23 (7.6%) | 97 (11.1%) | 47 (9.7%) | 30 (6.8%) | |
| Adjuvant chemotherapy | ||||||
| Yes | 1930 (82.8%) | 271 (80.4%) | 804 (81.5%) | 454 (88.5%) | 401 (81.0%) | 0.002 |
| No | 402 (17.2%) | 66 (19.6%) | 183 (18.5%) | 59 (11.5%) | 94 (19.0%) | |
| Adjuvant radiotherapy | ||||||
| Yes | 960 (41.6%) | 128 (38.6%) | 412 (42.3%) | 226 (44.7%) | 194 (39.2%) | 0.205 |
| No | 1348 (58.4%) | 204 (61.4%) | 563 (57.7%) | 280 (55.3%) | 301 (60.8%) | |
| Adjuvant endocrine therapy | ||||||
| Yes | 923 (39.6%) | 212 (63.7%) | 610 (61.7%) | 42 (8.3%) | 59 (11.8%) | <0.001 |
| No | 1406 (60.4) | 121 (36.3%) | 379 (38.3%) | 466 (91.7%) | 440 (88.2%) | |
| DFS (months) | ||||||
| Median | 29.0 | 36.0 | 27.0 | 20.0 | 18.5 | <0.001 |
| ≤24 | 998 (50.4%) | 86 (30.7%) | 369 (45.4%) | 286 (60.2%) | 257 (62.1%) | <0.001 |
| >24 | 984 (49.6%) | 194 (69.3%) | 444 (54.6%) | 189 (39.8%) | 157 (37.9%) | |